Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

ALK-Abello’s Pharmalgen Wins U.K. Cost-Agency Backing for Stings

Sept. 30 (Bloomberg) -- ALK-Abello A/S’s Pharmalgen won the preliminary backing of the U.K.’s health-cost agency for the treatment of severe reactions to bee and wasp stings.

As many as nine people die every year in the U.K. from allergic reactions, known as anaphylaxis, to the stings, the National Institute for Health and Clinical Excellence said in an e-mailed statement. Pharmalgen, an injection, prevents the reaction by desensitizing the immune system, said the agency, known as NICE.

A final decision probably will be made by February, NICE said. ALK-Abello is based in Hoersholm, Denmark.

To contact the reporter responsible for this story: Phil Serafino in Paris at pserafino@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.